Session 3
| Wednesday, April 28, 2021 |
| 11:15 - 12:15 |
Speaker
Dr Ricardo Cohen
The Center for Obesity and Diabetes, Oswaldo Cruz German Hospital, São Paulo, Brazil
Evidence that surgery can be used to place diabetes into remission
11:15 - 11:35Abstract
Evidence that surgery can be used to place diabetes into remission (Dr Ricardo Cohen)
T2D is associated with complex metabolic dysfunctions, leading to increased morbidity, mortality. Some strategies to prevent diabetes and obesity are essential. However, people who develop this disease should have access to all effective treatment options.As GLP-1 agonists and SGLT-2 inhibitors, anti-diabetes medications have shown positive effects on renal and cardiovascular outcomes, including decreased mortality. However, a considerable number of patients do not respond adequately to the best medical treatment. The gastrointestinal tract is an essential target for the management of T2D, as it has an essential role in metabolic homeostasis. There is bold evidence from large non-randomized studies and mid/long-term randomized controlled trials that showed that metabolic surgery could achieve glycemic control and reduce cardiovascular risk factors and mortality. Additional studies are needed; however, there is enough evidence, clinical and mechanistic, to support the indication of surgery in people with T2D and obesity that cannot control their diseases after the best medical treatment.
T2D is associated with complex metabolic dysfunctions, leading to increased morbidity, mortality. Some strategies to prevent diabetes and obesity are essential. However, people who develop this disease should have access to all effective treatment options.As GLP-1 agonists and SGLT-2 inhibitors, anti-diabetes medications have shown positive effects on renal and cardiovascular outcomes, including decreased mortality. However, a considerable number of patients do not respond adequately to the best medical treatment. The gastrointestinal tract is an essential target for the management of T2D, as it has an essential role in metabolic homeostasis. There is bold evidence from large non-randomized studies and mid/long-term randomized controlled trials that showed that metabolic surgery could achieve glycemic control and reduce cardiovascular risk factors and mortality. Additional studies are needed; however, there is enough evidence, clinical and mechanistic, to support the indication of surgery in people with T2D and obesity that cannot control their diseases after the best medical treatment.
Biography
Director of the Center for Obesity and Diabetes, Oswaldo Cruz German Hospital, Sao Paulo, Brazil.
Past President, Brazilian Society of Bariatric and Metabolic Surgery
Past President, IFSO-Latin American Chapter
Professor Helen Heneghan
Consultant Bariatric Surgeon at St. Vincent's University Hospital, Dublin
How can surgery be implemented in practice
11:35 - 11:55Biography
Professor Helen Heneghan (MB BCh BAO, PhD, FRCS) is a Consultant Bariatric Surgeon at St. Vincent’s University Hospital, Dublin and the Professor of Surgery at University College Dublin. She is a graduate of NUI Galway medical school, was awarded a PhD in the molecular expression of breast cancer and obesity from NUI Galway in 2012. She completed the RCSI Higher Surgical Training scheme in General Surgery in 2016. During her training, she spent two years on Fellowship in the Bariatric & Metabolic Institute in Cleveland Clinic, Ohio. She then completed her training with a Bariatric Fellowship in the UK (Chester & Liverpool). She has co-authored >70 publications in peer-reviewed journals and has written 5 book chapters on the topics of bariatric and endocrine surgery. Her research interests include obesity and cancer, diabetic kidney disease and bariatric surgery mechanisms.
Chair
Colm O'Boyle
Bon Secours Cork
